Tumor angiogenesis: therapeutic implications, N Engl J Med, vol.285, pp.1182-1186, 1971. ,
Microenvironmental regulation of tumor progression and metastasis, Nat Med, vol.19, pp.1423-1437, 2013. ,
Angiogenesis as a therapeutic target, Nature, vol.438, pp.967-974, 2005. ,
Antiangiogenic therapy for cancer: an update, Pharmacotherapy, vol.32, pp.1095-1111, 2012. ,
Anti-angiogenic therapy: concept to clinic, Microcirculation, vol.19, pp.115-125, 2012. ,
Anti-angiogenic drug discovery: lessons from the past and thoughts for the future, Expert Opin Drug Discov, vol.7, pp.723-743, 2012. ,
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents, Bioessays, vol.13, pp.31-36, 1991. ,
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature, vol.390, pp.404-407, 1997. ,
Resistance in the anti-angiogenic era: nay-saying or a word of caution?, Trends Mol Med, vol.9, pp.24-29, 2003. ,
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences, Drug Resist Updat, vol.6, pp.111-127, 2003. ,
Mechanisms of resistance to anti-angiogenesis therapies, Biochimie, vol.95, pp.1110-1119, 2013. ,
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy, J Hematol Oncol, vol.6, p.49, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00845842
Tumour endothelial cells acquire drug resistance in a tumour microenvironment, J Biochem, vol.153, pp.243-249, 2013. ,
The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis, Cancer, vol.98, pp.581-589, 2003. ,
Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment, Am J Pathol, vol.180, pp.1283-1293, 2012. ,
Effect of the breast-cancer resistance protein on atypical multidrug resistance, Lancet Oncol, vol.1, pp.169-175, 2000. ,
Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy, Curr Med Chem, vol.14, pp.689-701, 2007. ,
, Structure and function of the human breast cancer resistance protein (BCRP/ABCG2)
, Curr Drug Metab, vol.11, pp.603-617, 2010.
Localisation of breast cancer resistance protein in microvessel endothelium of human brain, Neuroreport, vol.13, pp.2059-2063, 2002. ,
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib, Anticancer Drugs, vol.21, issue.1, pp.3-11, 2010. ,
Anti-angiogenesis therapy in cancer: current challenges and future perspectives, Cancer Lett, vol.320, pp.130-137, 2012. ,
Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group, J Thorac Oncol, vol.7, pp.760-763, 2012. ,
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer, Clin Genitourin Cancer, vol.11, pp.175-181, 2013. ,
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer, Invest New Drugs, vol.31, pp.390-398, 2013. ,
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor, Cancer Chemother Pharmacol, vol.67, issue.1, pp.15-24, 2011. ,
Transient sunitinib resistance in gastrointestinal stromal tumors, N Engl J Med, vol.368, pp.2042-2043, 2013. ,
Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin, Cancer Res, vol.64, pp.2062-2069, 2004. ,
URL : https://hal.archives-ouvertes.fr/hal-00320014
Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells, Cancer Sci, vol.77, pp.1493-1500, 2005. ,
Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics, Drug Metab Pharmacokinet, vol.27, pp.631-639, 2012. ,
Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats, Drug Metab Dispos, vol.41, pp.1592-1597, 2013. ,
Cross resistance and collateral sensitivity studies in cancer chemotherapy, Adv Cancer Res, vol.7, pp.235-250, 1963. ,
Conference on obstacles to the control of acute leukemia. Studies on cross-resistance and collateral sensitivity (1962-1964), Cancer Res, vol.25, pp.1581-1595, 1965. ,
Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents, Front Oncol, vol.3, p.259, 2013. ,
Mechanisms of tumor resistance to small-molecule vascular disrupting agents: treatment and rationale of combination therapy, J Formos Med Assoc, vol.112, pp.115-124, 2013. ,